{
    "ticker": "MYI",
    "name": "Myriad Genetics, Inc.",
    "description": "Myriad Genetics, Inc. is a molecular diagnostic company dedicated to improving patient outcomes through innovative genetic testing services. Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad specializes in the development and commercialization of predictive medicine, particularly in the fields of oncology, urology, and women's health. The company is best known for its BRACAnalysis test, which assesses the risk of hereditary breast and ovarian cancer. Myriad's portfolio also includes tests for prostate cancer, endometrial cancer, and other hereditary cancer syndromes, as well as risk assessment tools for various health conditions. By leveraging advanced genomic technologies and extensive clinical data, Myriad aims to empower healthcare providers and patients with actionable insights that can guide treatment decisions and preventive care. With a strong commitment to research and development, Myriad is continuously working to expand its testing capabilities and improve the precision of its diagnostic tools. The company\u2019s mission is to save lives and improve the quality of life by providing comprehensive genetic information that drives personalized healthcare.",
    "industry": [
        "Healthcare",
        "Biotechnology"
    ],
    "headquarters": "Salt Lake City, Utah, USA",
    "founded": "1991",
    "website": "https://www.myriad.com",
    "ceo": "Paul J. Diaz",
    "social_media": {
        "twitter": "https://twitter.com/myriadgenetics",
        "linkedin": "https://www.linkedin.com/company/myriad-genetics/"
    },
    "investor_relations": "https://investors.myriad.com",
    "key_executives": [
        {
            "name": "Paul J. Diaz",
            "position": "CEO"
        },
        {
            "name": "Catherine A. H. T. K. H. Le",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Testing",
            "products": [
                "BRACAnalysis",
                "Prolaris",
                "EndoPredict"
            ]
        },
        {
            "category": "Women's Health Testing",
            "products": [
                "Foresight",
                "MyRisk"
            ]
        }
    ],
    "seo": {
        "meta_title": "Myriad Genetics, Inc. | Genetic Testing for Personalized Healthcare",
        "meta_description": "Explore Myriad Genetics, Inc., a leader in molecular diagnostics and genetic testing services that improve patient outcomes and guide treatment decisions.",
        "keywords": [
            "Myriad Genetics",
            "Genetic Testing",
            "Oncology",
            "BRACAnalysis",
            "Personalized Medicine"
        ]
    },
    "faq": [
        {
            "question": "What is Myriad Genetics known for?",
            "answer": "Myriad Genetics is known for its innovative genetic testing services, particularly in oncology and women's health."
        },
        {
            "question": "Who is the CEO of Myriad Genetics?",
            "answer": "Paul J. Diaz is the CEO of Myriad Genetics, Inc."
        },
        {
            "question": "Where is Myriad Genetics headquartered?",
            "answer": "Myriad Genetics is headquartered in Salt Lake City, Utah, USA."
        },
        {
            "question": "What are Myriad Genetics' main products?",
            "answer": "Myriad Genetics' main products include BRACAnalysis, Prolaris, and women's health tests like Foresight."
        },
        {
            "question": "When was Myriad Genetics founded?",
            "answer": "Myriad Genetics was founded in 1991."
        }
    ],
    "competitors": [
        "NTRA",
        "ILMN",
        "EXAS"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "REGN"
    ]
}